Embrace The Digital Revolution, But On Your Own Terms, John Nosta Says

Digital health and innovation strategist John Nosta talks about the need for medical technology companies to stay true to their technology roots and not get too attached to the "patient centricity" bandwagon. Also: innovating organically and "failing smart."

John Nosta, Nostalabs
John Nosta on the speaking circuit

Device companies are under pressure not only to be more of a solutions-provider and cost-saver to hospitals, but, increasingly, to establish more direct engagement with patients. With disruptive pressures from tech players like Apple and Google, and retail giants like Amazon and CVS, the push for medical device firms to engage patients more directly with the help of data analytics and digital tools is high. (Also see "Industry Is Falling Short In Digital Investments" - Medtech Insight, 24 September, 2018.)

MedTech Meeting

Nosta will offer a keynote address the MedTech Association's annual meeting in Syracuse, NY, on Nov. 14. The meeting runs Nov. 13-14.

But while there is no question the paradigm for health care is undergoing massive change, medtech firms shouldn't forget where their real expertise lies, argues digital-health specialist John Nosta.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Digital Technologies

ConcertAI Launches Generative AI-Powered Precision Suite

 

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Handheld Diagnostics: A Resurging Category That is Here to Stay

 

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.

More from Medtech Insight

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

Handheld Diagnostics: A Resurging Category That is Here to Stay

 

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

Execs On The Move: 12-23 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.